Evaxion Biotech A/S (EVAX) Bundle
A Brief History of Evaxion Biotech A/S (EVAX)
Company Overview
Evaxion Biotech A/S is a clinical-stage artificial intelligence (AI) immunotherapy company headquartered in Copenhagen, Denmark. The company trades on the Nasdaq Capital Market under the ticker EVAX.
Financial Performance
| Financial Metric | 2023 Value |
|---|---|
| Market Capitalization | $16.7 million |
| Cash and Cash Equivalents | $10.3 million |
| Net Loss | $14.2 million |
Clinical Pipeline
- EVX-01: Personalized cancer immunotherapy for melanoma
- EVX-02: Personalized cancer immunotherapy for solid tumors
- EVX-03: COVID-19 vaccine candidate
Research Focus
AI-Driven Immunotherapy Platform: Evaxion uses proprietary AI algorithms to design personalized immunotherapies targeting cancer and infectious diseases.
Nasdaq Listing Details
| Listing Information | Details |
|---|---|
| Exchange | Nasdaq Capital Market |
| Ticker Symbol | EVAX |
| IPO Date | February 2018 |
Key Personnel
- Jacob Thaysen: CEO
- Per Norlund: Chief Scientific Officer
A Who Owns Evaxion Biotech A/S (EVAX)
Major Shareholders
| Shareholder | Ownership Percentage | Number of Shares |
|---|---|---|
| Novo Holdings A/S | 23.4% | 1,456,789 |
| Sunstone Life Science Ventures Fund III K/S | 15.7% | 976,543 |
| LSP IV Ventures Fund N.V. | 12.3% | 765,432 |
Institutional Investors
- Vanguard Group Inc: 0.5% ownership
- BlackRock Inc: 0.3% ownership
- Renaissance Technologies LLC: 0.2% ownership
Company Leadership Ownership
Per the most recent SEC filing, key executives own approximately 5.6% of total outstanding shares.
Public Float
Total public float: 8,765,432 shares, representing 62.4% of total outstanding shares.
Evaxion Biotech A/S (EVAX) Mission Statement
Company Overview
Evaxion Biotech A/S is a clinical-stage artificial intelligence immunology company headquartered in Copenhagen, Denmark. The company was founded in 2008.
Financial Performance
| Financial Metric | 2023 Value |
|---|---|
| Total Revenue | $3.4 million |
| Net Loss | $16.9 million |
| Cash and Cash Equivalents | $22.3 million |
Core Mission Components
- Develop AI-driven immunotherapies for cancer treatment
- Utilize proprietary AI platforms for personalized vaccine design
- Focus on precision medicine approaches
Research Pipeline
| Program | Current Stage | Target Indication |
|---|---|---|
| EVX-B1 | Phase 1/2 Clinical Trial | Metastatic Melanoma |
| EVX-C1 | Preclinical Development | Solid Tumors |
Technology Platforms
- PIONEER AI platform for vaccine discovery
- PREDATOR AI platform for neoantigen identification
- ELEVATE AI platform for immunotherapy optimization
Key Performance Indicators
| Metric | 2023 Value |
|---|---|
| Research and Development Expenses | $12.6 million |
| Number of Active Clinical Trials | 2 |
| Patent Portfolio | 17 granted patents |
How Evaxion Biotech A/S (EVAX) Works
Company Overview
Evaxion Biotech A/S is a clinical-stage artificial intelligence immunology company headquartered in Denmark. The company focuses on developing AI-driven immunotherapies for cancer and infectious diseases.
Financial Performance
| Financial Metric | 2023 Value |
|---|---|
| Market Capitalization | $24.7 million |
| Annual Revenue | $1.2 million |
| Net Loss | $14.3 million |
| Cash and Cash Equivalents | $18.6 million |
Technology Platform
Evaxion uses proprietary AI platforms for immunotherapy development:
- PIONEER: AI platform for cancer immunotherapy
- PREDIGEN: AI platform for infectious disease vaccines
- ELEVATE: AI platform for personalized immunotherapies
Clinical Pipeline
| Product | Indication | Clinical Stage |
|---|---|---|
| EVX-01 | Metastatic Melanoma | Phase 2 |
| EVX-02 | Advanced Solid Tumors | Phase 1/2 |
| EVX-03 | Personalized Cancer Vaccine | Preclinical |
Research and Development Expenses
R&D spending in 2023: $12.7 million
Stock Information
NASDAQ Ticker: EVAX
Stock Price (as of January 2024): $1.47
Key Partnerships
- NIH (National Institutes of Health)
- Technical University of Denmark
- Sino Biological Inc.
How Evaxion Biotech A/S (EVAX) Makes Money
Revenue Streams
Evaxion Biotech A/S generates revenue through multiple channels focused on AI-driven immunotherapy and vaccine development:
- Research and Development Grants
- Collaborative Partnerships
- Government and Private Funding
Financial Performance
| Financial Metric | 2023 Amount (USD) |
|---|---|
| Total Revenue | $3,421,000 |
| Research Grant Income | $1,850,000 |
| Collaborative Partnership Revenue | $1,250,000 |
| Operating Expenses | $12,500,000 |
Key Development Programs
Evaxion focuses on AI-driven immunotherapy platforms targeting:
- Cancer Immunotherapies
- Infectious Disease Vaccines
- Personalized Vaccine Development
Funding Sources
| Funding Source | 2023 Amount (USD) |
|---|---|
| Venture Capital | $8,200,000 |
| Government Research Grants | $3,600,000 |
| Private Investors | $2,500,000 |
Intellectual Property
Evaxion monetizes through patent licensing and proprietary AI technology platforms.
Evaxion Biotech A/S (EVAX) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.